TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07782996: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolle

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 370 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07782996 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07782996 Rescue Dossier →